GENOVA Inc. (JP:9341)
:9341
Want to see JP:9341 full AI Analyst Report?
Top Page
GENOVA Inc.
(9341)
Select Model
Select Model
Rating:54Neutral
Price Target:
¥602.00
▲(3.44% Upside)
Action:Reiterated
Date:05/15/26
The score is held back primarily by weakened fundamentals in 2026—sharp margin/ROE compression and a significant cash-flow reversal with negative free cash flow. Technical indicators also reflect weak momentum. A high dividend yield provides some support, but the elevated P/E reduces valuation comfort given recent earnings-quality pressure.
Positive Factors
Strong multi-year revenue growth
GENOVA's sustained ~24% revenue growth in 2026 and multi-year expansion indicates durable demand for its healthcare information services. Strong top-line momentum supports reinvestment in products, scale economies and market-share gains, reducing execution risk over the medium term.
Negative Factors
Material cash-flow deterioration
A sharp reversal to weak operating cash flow and negative free cash flow undermines cash conversion and raises reliance on external funding. This constrains capital allocation, dividend sustainability and near-term reinvestment, and elevates liquidity risk if the cash shortfall persists.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong multi-year revenue growth
GENOVA's sustained ~24% revenue growth in 2026 and multi-year expansion indicates durable demand for its healthcare information services. Strong top-line momentum supports reinvestment in products, scale economies and market-share gains, reducing execution risk over the medium term.
Read all positive factors
GENOVA Inc. (9341) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥10.08B
Dividend Yield5.3%
Average Volume (3M)127.01K
Price to Earnings (P/E)34.6
Beta (1Y)0.94
Revenue Growth15.59%
EPS Growth-80.09%
CountryJP
Employees352
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)52.50
Shares Outstanding17,837,600
10 Day Avg. Volume126,090
30 Day Avg. Volume127,006
Financial Highlights & Ratios
PEG Ratio-0.43
Price to Book (P/B)1.38
Price to Sales (P/S)0.82
P/FCF Ratio-202.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)157.5
Revenue Forecast (FY)¥15.40B
GENOVA Inc. Business Overview & Revenue Model
Company Description
GENOVA, Inc. engages in the medical platform and smart clinic businesses in Japan. It offers Medical Doc, a platform that distributes articles for medical institutions, patient experience articles, treatment videos, and medical-related articles. I...
How the Company Makes Money
null...
GENOVA Inc. Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
76
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.32B | 11.57B | 10.01B | 8.68B | 6.51B | 4.80B |
| Gross Profit | 6.74B | 6.47B | 7.38B | 6.55B | 4.79B | 3.50B |
| EBITDA | 1.34B | 543.85M | 2.11B | 2.38B | 1.79B | 1.09B |
| Net Income | 930.62M | 275.40M | 1.41B | 1.73B | 1.26B | 686.27M |
Balance Sheet | ||||||
| Total Assets | 7.58B | 10.26B | 8.53B | 8.20B | 5.41B | 2.82B |
| Cash, Cash Equivalents and Short-Term Investments | 5.18B | 5.32B | 5.87B | 5.97B | 3.86B | 1.65B |
| Total Debt | 8.33M | 735.71M | 20.84M | 377.78M | 28.25M | 163.50M |
| Total Liabilities | 1.16B | 3.36B | 1.53B | 2.16B | 1.37B | 1.33B |
| Stockholders Equity | 6.41B | 6.90B | 7.00B | 6.04B | 4.04B | 1.49B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -46.98M | 1.06B | 1.77B | 1.11B | 513.36M |
| Operating Cash Flow | 0.00 | 53.85M | 1.19B | 1.82B | 1.20B | 623.77M |
| Investing Cash Flow | 0.00 | -809.75M | -275.93M | -94.24M | -113.45M | -179.06M |
| Financing Cash Flow | 0.00 | 199.63M | -1.01B | 376.82M | 1.13B | 59.88M |
GENOVA Inc. Technical Analysis
Positive
582.00
Price Trends
566.45
Positive
567.67
Positive
584.08
Negative
Market Momentum
0.95
Negative
56.11
Neutral
29.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:9341, the sentiment is Positive. The current price of 582 is above the 20-day moving average (MA) of 560.75, above the 50-day MA of 566.45, and below the 200-day MA of 584.08, indicating a neutral trend. The MACD of 0.95 indicates Negative momentum. The RSI at 56.11 is Neutral, neither overbought nor oversold. The STOCH value of 29.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:9341.
GENOVA Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | ¥10.08B | 34.60 | ― | 5.30% | 15.59% | -80.09% | |
52 Neutral | ¥7.40B | 35.90 | ― | ― | 17.70% | -27.54% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥74.70B | -232.45 | 5.76% | ― | 23.30% | -56.05% | |
44 Neutral | ¥2.28B | -4.36 | ― | ― | 18.86% | 38.80% |
* Healthcare Sector Average
JP:9341
GENOVA Inc.
579.00
-100.37
-14.77%
JP:4480
Medley
2,289.00
-736.00
-24.33%
JP:4438
Welby Inc.
268.00
-76.00
-22.09%
JP:9218
Mental Health Technologies Co. Ltd.
704.00
19.91
2.91%
JP:366A
Wellness Communications Corporation
1,105.00
-658.59
-37.34%
GENOVA Inc. Corporate Events
GENOVA Books Extraordinary Non-Consolidated Gain From Subsidiary Merger
May 13, 2026
GENOVA Inc. has completed an absorption-type merger of its wholly owned subsidiary GENOVA DESiGN Inc., effective April 1, 2026, resulting in a book-value difference between the net assets received and the shares previously held. This transaction w...
GENOVA Books Extraordinary Income After Director’s Stock Options Lapse
May 13, 2026
GENOVA Inc. said it will recognize extraordinary income after stock acquisition rights previously granted to a director lapsed when the executive resigned on April 30, 2026. The lapse of the 7th and 8th tranches of these stock options, whose exerc...
Genova’s Profit Slumps Despite Higher Sales, Dividend Held as Company Forecasts Sharp Rebound
May 13, 2026
Genova Inc. reported consolidated net sales of ¥11,565 million for the fiscal year ended March 31, 2026, up 15.6% year on year, but operating profit plunged 80.2% to ¥400 million and profit attributable to owners of parent fell 80.5% to ...
GENOVA to Book Extraordinary Non-Consolidated Gain From Subsidiary Merger
May 13, 2026
GENOVA Inc. has completed an absorption-type merger of its wholly owned subsidiary GENOVA DESiGN Inc., effective April 1, 2026, as part of its internal reorganization. The transaction generated a difference between the net assets received and the ...
GENOVA Books Extraordinary Income on Lapsed Stock Options After Director Exit
May 13, 2026
GENOVA Inc. will recognize extraordinary income after stock acquisition rights previously granted to a director lapsed when the allottee resigned on April 30, 2026 and no longer met the exercise conditions. The company will record a gain on revers...
Genova Profit Plunges Despite Sales Growth, Payout Ratio Soars as Firm Bets on 2027 Rebound
May 13, 2026
Genova Inc. reported consolidated net sales of ¥11.56 billion for the fiscal year ended March 31, 2026, up 15.6% year on year, but operating profit collapsed 80.2% to ¥400 million and profit attributable to owners fell 80.5% to ¥275...
GENOVA cuts profit outlook despite revenue lift from dental acquisition
May 8, 2026
GENOVA Inc. revised its full-year consolidated earnings forecast for the fiscal year ending March 31, 2026, raising projected net sales but cutting profit estimates due to margin pressure from its newly acquired dental distribution business and ta...
GENOVA Director Akinao Ueda Resigns, Board Structure Maintained
Apr 30, 2026
GENOVA Inc. announced that Board Director and Executive Officer Akinao Ueda has resigned from his position effective April 30, 2026, citing personal reasons. The company emphasized that, despite this change, it will continue to meet the legally re...
GENOVA Reshapes Executive Lineup to Bolster Healthcare Business Structure
Apr 1, 2026
GENOVA Inc. announced a series of executive officer personnel changes effective April 1, 2026, largely reappointing existing executives to their current or slightly adjusted roles across key sales, branch and corporate divisions. The reshuffle mai...
GENOVA to Acquire Akasaka Shizaisha, Expanding Dental Distribution Network
Apr 1, 2026
GENOVA Inc. has resolved to acquire Akasaka Shizaisha Co., Ltd., a long-established wholesaler of dental materials serving dental technicians, converting it into a subsidiary as part of its strategy to build a comprehensive dental distribution pla...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.